🇺🇸 FDA
Pipeline program

REGN2810

R2810-ONC-1606

Phase 1 small_molecule completed

Quick answer

REGN2810 for Melanoma is a Phase 1 program (small_molecule) at Regeneron UK Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Regeneron UK Limited
Indication
Melanoma
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials